Keywords: AstrZeneca, Seroquel, Monotherapy, Major depressive disorder, FDA

Safety and clinical benefits of AstraZeneca’s Seroquel XR need to be demonstrated for its approval as an MDD monotherapy, says DR

Article | 28 January 2010

Print This

The recent decision by the US Food and Drug Administration to grant approval of Anglo-Swedish drug major AstraZeneca's Seroquel XR ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in